Cogent Biosciences Inc
COGT
Market Cap$547.65M
Close$
$0.78
83.8% downside
Current Fair Value
83.8% downsideOvervalued by 83.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $547.65 Million |
|---|---|
| Enterprise Value | $466.95 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.49 |
| Beta | 0.22 |
| Outstanding Shares | 110,461,729 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -2.08 |
|---|---|
| PEG | -7.54 |
| Price to Sales | - |
| Price to Book Ratio | 2.41 |
| Enterprise Value to Revenue | 83.56 |
| Enterprise Value to EBIT | -1.79 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cogent Biosciences Inc
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently ...